I think with several cases bought back from the dead the US govt will find a way to comprimise with gsk on testing design and push this forward - it's very interesting that relenza iv was able to reverse viral replication so suddenly in an advanced patient- it's systemic potency must be far greater than tamiflu to have this outcome where no tamiflu resistance was present- as posted above is a very important point. Anyone know if the iv formulation is the same as the powder- or does it need to have something added to get a iv format- and how does this affect cost/ rate of production?
If it's as easy as adding the existing formulation to an iv line - it could end up being a blockbuster.
Then how about IV Lani???
- Forums
- ASX - By Stock
- BTA
- tamiflu resistance not the point here
tamiflu resistance not the point here, page-3
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online